Marktanalyse - Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue

Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue


Summary


GBI Research’s new report, 'Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue” provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in Argentina. The report analyzes the overall pharma and clinical trials market in Argentina. Furthermore, the report provides profiles for the leading pharmaceutical companies, Contract Research Organizations (CROs) and distributors; analyzes the macroeconomic environment; describes the healthcare regulations of Argentina and analyzes the strategic consolidations that shape the Argentine pharmaceutical market. This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Argentina is the third largest market for pharmaceuticals in Latin America. There are 230 registered laboratories and 110 manufacturing plants in Argentina and most of these are domestic. Over 80% of the laboratories and manufacturing plants are located in urban areas, especially in the province of Buenos Aires. The market has shown significant growth ever since the economic crisis during 2001-2002, due to the ageing population and high proportion of elderly people in the country’s population; growth in government healthcare expenditure; increased internal consumption of medicines and increasing prevalence of diseases which come under major therapy areas such as cardiovascular, Central Nervous System (CNS), gastrointestinal and metabolism, among others. A similarly positive trend is expected in the future due to a number of facts such as increasing internal consumption, a rise in the elderly population favorable strategic consolidations and increasing government healthcare expenditure. GBI Research expects the market to exhibit double-digit growth during the period 2010—2015.

GBI Research has analyzed the pharmaceutical market in Argentina and found that it is dominated by domestic pharmaceutical companies. Most of the domestic laboratories in Argentina are private and they explored the domestic market. The prescription drugs’ market accounted for about 90% of the market. Despite issues relating to Intellectual Property (IP) laws, multinational pharmaceutical companies are expanding their market presence by acquiring small domestic laboratories and through licensing agreements. The Argentine pharmaceutical market is one of the top emerging markets which have shown an annual growth rate of up to 22% in recent years. The economic growth of the country has been above the global average and the healthcare sector’s expenditure accounted for approximately 10% of the country’s GDP, of which the government’s healthcare spending accounted for over 60%.

According to GBI Research’s analysis, Argentina is an attractive market for pharmaceuticals and clinical trials due to a number of factors, such as the aligned legal provisions by Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) (the principal regulatory body in Argentina) and Ministry of Health (MOH); increasing government healthcare spending; favorable healthcare infrastructure; public healthcare programs and a considerable number of licensing, M&As and co-development deals.


Scope

- The overall pharmaceuticals and clinical trials markets in Argentina.
- A pharmaceutical market characterization of the Argentine pharmaceutical market, including market size data and forecast clinical trials, healthcare regulations, pricing, and major marketing and distribution channels.
- The historic and forecast growth of the clinical trials market in Argentina.
- Analysis of the leading segments within the Argentinean pharmaceutical industry.
- Key Argentine market drivers and restraints that have a significant impact on the market.
- Profiles of the leading companies in the pharma, distribution and CRO sectors.
- Key M&A activities, licensing and co-development deals that have taken place between 2004 and 2011.


Reasons to buy

- Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
- Devise a better-tailored national strategy through an understanding of the key drivers and barriers of the country’s pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


Press Release:

Argentina Takes Hold of Public Healthcare.

Argentina is boosting the health of their citizens thanks to strong government schemes that are providing medical attention to those that need it, while financially supporting the country’s in house pharmaceutical production, according to a new report from healthcare experts GBI Research.

The new report shows that the Argentine pharmaceutical market is expected to witness significant growth in the near future, based on predicted increases in government healthcare spending, which are set to support the country’s citizens by providing comprehensive medical care.

While 15 % of total government expenditure was spent on healthcare in 2009, a higher ratio than that of most emerging countries, schemes such as the Remediar program, which runs a network distributing essential drugs directly to local clinics in low-income neighborhoods and is funded by the government and the Ministry of Health (MOH), are set to further increase expenditure in coming years.

Argentina’s pharmaceutical market is one of the fastest-growing markets in Latin America, having blossomed since the country’s economic crisis of 2001-2002.

Amidst the financial turmoil, large domestic companies acquired the divested manufacturing facilities of multinational pharmaceutical companies and established themselves in the market to support the country’s healthcare needs.

The Argentine pharmaceutical market is therefore now dominated by local pharmaceutical companies, which accounted for 58% of the industry’s revenue in 2010. Pharmaceuticals produced by domestic laboratories within the country accounted for around 94% of the revenue, with only the remaining 6% of drug sales relying on foreign imports.

Most domestic laboratories in Argentina are private and dominate the local market due to strong brand awareness, effective business strategies, and high levels of influence on drugstores, pharmacies, healthcare professionals and patients. Strong associations also exist with experienced talent pools such as Cámara Industrial de Laboratorios Farmacéuticos

Argentinos (CILFA) and Cámara Empresaria de Laboratorios Farmacéuticos (Cooperala). The Argentine pharmaceutical market was estimated at $4.3 billion in 2010. GBI Research estimates that the market will grow at a Compound Annual Growth Rate (CAGR) of 10.6% during the given forecast period (2010-2015).

*Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue

This report provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in Argentina. It analyzes the overall pharmaceutical and clinical trials market in Argentina, and provides profiles for the leading pharmaceutical companies, Contract Research Organizations (CROs) and distributors; analyzes the macroeconomic environment; describes the healthcare regulations of Argentina and analyzes the strategic consolidations that shape the Argentine pharmaceutical market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 8

1.2 List of Figures 9

2 Emerging Pharmaceutical Market: Argentina - Introduction 11

2.1 Overview 11

3 Emerging Pharmaceutical Market: Argentina - Industry Characterstics 12

3.1 Market Size and Forecast 12

3.1.1 Overview 12

3.1.2 Revenue Forecast 12

3.1.3 Prescription vs. OTC Drugs 13

3.1.4 Revenue Analysis by Therapy Area 14

3.2 Competitive Landscape 15

3.2.1 Overview 15

3.2.2 Market Share - Domestic vs. Foreign 16

3.2.3 Market Share Analysis 17

3.2.4 Major Domestic Players 18

3.2.5 Major Foreign Players 20

3.3 Pharmaceutical Trade - Forecast 24

3.3.1 Pharmaceutical Exports, Imports and Balance of Trade 24

3.3.2 Exports by Destination 26

3.3.3 Imports by Source 27

3.4 Pharmaceutical Marketing and Distribution 28

3.4.1 Pharmaceutical Distribution System 28

3.4.2 Major Distributors 29

3.5 Clinical Trials 30

3.5.1 Number of Clinical Trials Registered in Argentina 30

3.5.2 Number of Clinical Trials Registered in Argentina - Trend Analysis 31

3.5.3 Number of Registered Clinical Trial Sites per Million Population 32

3.6 Healthcare System in Argentina 33

3.6.1 Public Healthcare 33

3.6.2 Private Healthcare 34

3.7 PESTL Analysis 34

4 Emerging Pharmaceutical Market: Argentina - Macroeconomic Environment 35

4.1 Demographic Analysis 35

4.1.1 Population Size, Growth, and Structure 35

4.1.2 Patient Availability for Major Diseases 36

4.1.3 Forecasts of Major Diseases 38

4.2 National/Domestic Income 43

4.2.1 Annual GDP Growth Rate - Comparative Analysis 43

4.2.2 Gross National Income (GNI) per Capita in Argentina 44

4.3 Expenditure on Health 45

4.3.1 Total Healthcare Expenditure - Trend Analysis 46

4.3.2 Healthcare Expenditure - Comparative Analysis 48

4.4 Healthcare Workforce and Infrastructure 50

4.4.1 Healthcare Workforce 50

4.4.2 Healthcare Infrastructure 53

5 Emerging Pharmaceutical Market: Argentina - Healthcare Regulation 54

5.1 Pharmaceutical Regulation in Argentina 54

5.1.1 National Healthcare Policy Framework in Argentina 54

5.1.2 Intellectual Property Laws and Medicines 54

5.1.3 Generics Law 55

5.1.4 Legal Provisions 55

5.2 Clinical Trial and Drug Approval Process 58

5.2.1 Approval Process for Clinical Trials in Argentina 58

5.2.2 Registration of Drugs 59

5.3 Pricing and Regulation 60

5.3.1 Cost of Medical Treatment 60

5.3.2 Pricing of Medicines 61

6 Emerging Pharmaceutical Market: Argentina - Strategic Consolidations 62

6.1 Overview 62

6.2 Mergers and Acquisitions 63

6.2.1 Deals by Year 63

6.2.2 Deal by Value 64

6.2.3 Top 10 M&A Deals 65

6.3 Licensing Agreements 68

6.3.1 Licensing Agreements by Year 68

6.3.2 Deals by Value 69

6.3.3 Top 10 Licensing Deals 70

6.4 Co-Development Deals 75

6.4.1 Deals by Year 75

6.4.2 Deals by Value 76

6.4.3 Top 10 Co-Development Deals 77

7 Emerging Pharmaceutical Market: Argentina - Contract Research Organizations (CRO) Landscape 81

7.1 Contract Research Organization (CRO) Sector in Argentina 81

7.1.1 Clinical Trial Market Size and Growth 81

7.2 CRO Profiles 82

7.2.1 Abel Santos & Asociados 82

7.2.2 Activa CRO 83

7.2.3 Blanchard & Asociados 84

7.2.4 EGCP 85

7.2.5 Klixar 86

7.2.6 LatinClin 87

7.2.7 MMatiss 88

7.2.8 ECLA 89

7.2.9 Quintiles 90

7.2.10 Covance 91

7.2.11 Charles River 92

7.2.12 INC Research 93

7.2.13 Theorem Clinical Research 94

8 Emerging Pharmaceutical Market: Argentina - Appendix 95

8.1 Market Definitions 95

8.2 Abbreviations 95

8.3 Research Methodology 97

8.3.1 Industry Characteristics 97

8.3.2 Macroeconomic Environment 97

8.3.3 Healthcare Regulations 97

8.3.4 Strategic Consolidations 97

8.3.5 CRO Landscape 97

8.4 Contact Us 98

8.5 Disclaimer 98

8.6 Sources 98





1.1 List of Tables

Table 1: Emerging Pharmaceutical Market: Argentina, Revenue Forecast ($bn), 2010-2015 12

Table 2: Emerging Pharmaceutical Market: Argentina, Market Share of Prescription and OTC Drugs, 2010 13

Table 3: Emerging Pharmaceutical Market: Argentina, Market Share of Domestic and Foreign Companies, 2010 16

Table 4: Emerging Pharmaceutical Market: Argentina, Top 10 Pharmaceutical Companies - Market Share Analysis, %, 2009 18

Table 5: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2005-2010 24

Table 6: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2010-2015 25

Table 7: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, 2010 30

Table 8: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, 2005-2010 31

Table 9: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of the Number of Registered Clinical Trial Sites per Million Population in Six Major Countries in Latin America, 2010 32

Table 10: Emerging Pharmaceutical Market, Argentina, Population Forecast (‘000), 2000-2050 35

Table 11: Emerging Pharmaceutical Market, Argentina, Patient Population (‘000), 2010 36

Table 12: Emerging Pharmaceutical Market, Argentina, Mortality by Disease Categories (‘000), 2010 37

Table 13: Emerging Pharmaceutical Market, Argentina, Population Forecast for HIV (‘000), 2010-2015 38

Table 14: Emerging Pharmaceutical Market, Argentina, Population Forecast for CVD (‘000), 2010-2015 39

Table 15: Emerging Pharmaceutical Market, Argentina, Population Forecast for Diabetes (‘000), 2010-2015 40

Table 16: Emerging Pharmaceutical Market, Argentina, Population Forecast for Cancer (‘000), 2010-2015 41

Table 17: Emerging Pharmaceutical Market, Argentina, Population Forecast for COPD and Asthma (‘000), 2010-2015 42

Table 18: Emerging Pharmaceutical Market: Argentina, Four Major Pharmaceutical Markets in Latin America, Annual GDP Growth Rate, %, 2010 43

Table 19: Emerging Pharmaceutical Market, Argentina, GNI per Capita, $, 2005-2010 44

Table 20: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure as Percentage of GDP, %, 2005-2009 46

Table 21: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure per Capita, $, 2005-2009 47

Table 22: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, %, 2009 48

Table 23: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Per Capita Expenditure on Health, Argentina, Mexico and BRIC Countries, $, 2009 49

Table 24: Emerging Pharmaceutical Market: Argentina, Number of Healthcare Personnel and Density Per 10,000 Population, 2011 50

Table 25: Emerging Pharmaceutical Market: Argentina, BRIC Countries, Argentina, Comparative Analysis of Density of Healthcare Personnel and per 10,000 Population, 2011 51

Table 26: Emerging Pharmaceutical Market: Argentina, The US, The UK and Brazil, Comparative Analysis of Growth Rate of Principal Investigators, %, 2001-2006 52

Table 27: Emerging Pharmaceutical Market: Argentina, Healthcare Infrastructure and Density Per 10,000 Population, 2011 53

Table 28: Emerging Pharmaceutical Market: Argentina, Number of Hospitals By Province and City, 2011 53

Table 29: Clinical Trials in Argentina, Cost Comparison Argentina Versus the US, $, 2010 60

Table 30: Emerging Pharmaceutical Market, Argentina, Deals by Type (%), 2004-2011 62

Table 31: Emerging Pharmaceutical Market, Argentina, M&A Deals by Year, 2004-2011 63

Table 32: Emerging Pharmaceutical Market, Argentina, M&A Deals by Value, 2004- 2011 64

Table 33: Emerging Pharmaceutical Market, Argentina, Top 10 M&A Deals, $m, 2004- 2011 65

Table 34: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Year, 2004-2011 68

Table 35: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Value (%), 2004-2011 69

Table 36: Emerging Pharmaceutical Market, Argentina, Top 10 Licensing Agreements, 2004- 2011 70

Table 37: Emerging Pharmaceutical Market, Argentina, Co-development Deals by Year, 2004-2011 75

Table 38: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Value (%), 2004-2011 76

Table 39: Emerging Pharmaceutical Market, Argentina, Top 10 Co-Development Deals, 2004-2011 77

Table 40: Emerging Pharmaceutical Market: Argentina, Clinical Trial Market in Argentina, Revenue, $m, 2010-2015 81





1.2 List of Figures

Figure 1: Emerging Pharmaceutical Market: Argentina, Revenue Forecast ($bn), 2010-2015 12

Figure 2: Emerging Pharmaceutical Market: Argentina, Market Share of Prescription and OTC Drugs, 2010 13

Figure 3: Emerging Pharmaceutical Market: Argentina, Revenue Analysis by Therapy Area (%), 2010 14

Figure 4: Emerging Pharmaceutical Market: Argentina, Market Share of Domestic and Foreign Companies (%), 2010 16

Figure 5: Emerging Pharmaceutical Market: Argentina, Top 10 Pharmaceutical Companies - Market Share Analysis (%), 2009 17

Figure 6: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Trade Forecast, $m, 2005-2015 24

Figure 7: Emerging Pharmaceutical Market: Argentina, Share of Major Export Destinations of Argentina, %, 2010 26

Figure 8: Emerging Pharmaceutical Market: Argentina, Share of Major Sources of Argentine Imports, %, 2010 27

Figure 9: Emerging Pharmaceutical Market: Argentina, Pharmaceutical Distribution System, 2010 28

Figure 10: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered, %, 2010 30

Figure 11: Emerging Pharmaceutical Market: Argentina, Number of Clinical Trials Registered - Trend Analysis, 2005-2010 31

Figure 12: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of the Number of Registered Clinical Trial Sites per Million Population in Six Major Countries in Latin America, 2010 32

Figure 13: Emerging Pharmaceutical Market: Argentina, PESTL Analysis 34

Figure 14: Emerging Pharmaceutical Market, Argentina, Population Forecast (‘000), 2000-2050 35

Figure 15: Emerging Pharmaceutical Market, Argentina, Patient Population (‘000), 2010 36

Figure 16: Emerging Pharmaceutical Market, Argentina, Mortality by Disease Categories, %, 2010 37

Figure 17: Emerging Pharmaceutical Market, Argentina, Population Forecast for HIV (‘000), 2010-2015 38

Figure 18: Emerging Pharmaceutical Market, Argentina, Population Forecast for CVD (‘000), 2010-2015 39

Figure 19: Emerging Pharmaceutical Market, Argentina, Population Forecast for Diabetes (‘000), 2010-2015 40

Figure 20: Emerging Pharmaceutical Market, Argentina, Population Forecast for Cancer (‘000), 2010-2015 41

Figure 21: Emerging Pharmaceutical Market, Argentina, Population Forecast for COPD and Asthma (‘000), 2010-2015 42

Figure 22: Emerging Pharmaceutical Market: Argentina, Four Major Pharmaceutical Markets in Latin America, Annual GDP Growth Rate, %, 2010 43

Figure 23: Emerging Pharmaceutical Market, Argentina, GNI per Capita, $, 2005-2010 44

Figure 24: Emerging Pharmaceutical Market: Argentina, Components of Healthcare Expenditure, %, 2009 45

Figure 25: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure as Percentage of GDP, %, 2005-2009 46

Figure 26: Emerging Pharmaceutical Market: Argentina, Total Healthcare Expenditure per Capita, $, 2005-2009 47

Figure 27: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, %, 2009 48

Figure 28: Emerging Pharmaceutical Market: Argentina, Comparative Analysis of Per Capita Expenditure on Health, Argentina, Mexico and BRIC Countries, $, 2009 49

Figure 29: Emerging Pharmaceutical Market: Argentina, Density of Healthcare Personnel Per 10,000 Population, 2011 50

Figure 30: Emerging Pharmaceutical Market: Argentina, BRIC Countries, Argentina, Comparative Analysis of Density of Healthcare Personnel and per 10,000 Population, 2011 51

Figure 31: Emerging Pharmaceutical Market: Argentina, The US, The UK and Brazil, Comparative Analysis of Growth Rate of Principal Investigators, %, 2001-2006 52

Figure 32: Clinical Trials in Argentina, Clinical Trial Regulation Approval Process, 2011 58

Figure 33: Emerging Pharmaceutical Market, Argentina, Deals by Type (%), 2004-2011 62

Figure 34: Emerging Pharmaceutical Market, Argentina, M&A Deals by Year, 2004-2011 63

Figure 35: Emerging Pharmaceutical Market, Argentina, M&A Deals by Value (%), 2004- 2011 64

Figure 36: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Year, 2004-2011 68

Figure 37: Emerging Pharmaceutical Market, Argentina, Licensing Agreements by Value (%), 2004-2011 69

Figure 38: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Year, 2004-2011 75

Figure 39: Emerging Pharmaceutical Market, Argentina, Co-Development Deals by Value (%), 2004-2011 76

Figure 40: Emerging Pharmaceutical Market: Argentina, Clinical Trial Market in Argentina, Revenue, $m, 2010-2015 81

Figure 41: Emerging Pharmaceutical Market, Argentina, Abel Santos & Asociados, Company Profile, 2011 82

Figure 42: Emerging Pharmaceutical Market, Argentina, Activa CRO, Company Profile, 2011 83

Figure 43: Emerging Pharmaceutical Market, Argentina, Blanchard & Asociados, Company Profile, 2011 84

Figure 44: Emerging Pharmaceutical Market Argentina, EGCP, Company Profile, 2011 85

Figure 45: Emerging Pharmaceutical Market, Argentina, Klixar, Company Profile, 2011 86

Figure 46: Emerging Pharmaceutical Market, Argentina, LatinClin, Company Profile, 2011 87

Figure 47: Emerging Pharmaceutical Market, Argentina, Mmatiss, Company Profile, 2011 88

Figure 48: Emerging Pharmaceutical Market, Argentina, ECLA, Company Profile, 2011 89

Figure 49: Emerging Pharmaceutical Market, Argentina, Quintiles, Company Profile, 2011 90

Figure 50: Emerging Pharmaceutical Market, Argentina, Covance, Company Profile, 2011 91

Figure 51: Emerging Pharmaceutical Market Argentina, Charles River, Company Profile, 2011 92

Figure 52: Emerging Pharmaceutical Market, Argentina, INC Research, Company Profile, 2011 93

Figure 53: Emerging Pharmaceutical Market, Argentina, Theorem Clinical Research, Company Profile, 2011 94

• ICT Spend Predictions in Large Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized US Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Brazilian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Canadian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small French Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small German Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Mexican Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small UK Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013